SIO Central : Most Recent IO Insights

Resources

January 26, 2023

.NEWS FROM SIO

Society of Interventional Oncology Announces First Site Approved for Enrollment in ACCLAIM Clinical Trial

LEARN MORE

Thanks for attending SIO2023 — Save the date for SIO2024!

SPONSORED CONTENT

Promoted by NeuWave Medical

How do treatment margins impact local lesion control? Learn here!
How does Ablation Confirmation with intelligent visualization and guidance tools help optimize procedural outcomes? See the data from 3 publications here!
Want to learn more? Contact NEUWAVE today!

.INDUSTRY NEWS

Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma: A Bibliometric and Knowledge-Map Analysis
Frontiers in Oncology via PubMed
In recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. Although several studies have been published, no bibliometric analysis have been conducted on this topic.

READ MORE

PRODUCT SHOWCASE

OPuS One Clinical Study News
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.

LEARN MORE

Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC
Journal of Hepatocelluar Carcinoma via PubMed
This study sought to evaluate treatment response, survival and safety of a novel TACE using combination of ethanol-Lipiodol mixture and drug-eluting beads in patients with large unresectable HCC, single tumor >8 cm or multiple tumors with the largest tumor diameter >5 cm and total tumor diameter >10 cm.

READ MORE

Immune-Related Gene Signature To Predict TACE Refractoriness in Patients With Hepatocellular Carcinoma Based on Artificial Neural Network
Frontiers in Genetics via PubMed
Transarterial chemoembolization (TACE) is the standard treatment option for intermediate-stage hepatocellular carcinoma (HCC), while response varies among patients. This study aimed to identify novel immune-related genes (IRGs) and establish a prediction model for TACE refractoriness in HCC patients based on machine learning methods.

READ MORE

SPONSORED CONTENT

Promoted by Forme Financial

PNI-Based Nomograms to Predict Tumor Progression and Survival for Patients with Unresectable Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization
Journal of Clinical Medicine via PubMed
The relationship between the prognostic nutritional index (PNI) and the prognosis of malignancy has been increasingly mentioned in recent research. This study aimed to construct nomograms based on the PNI to predict tumor progression and survival in patients with unresectable hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE).

READ MORE

IO Insights

Connect with SIO

Hailey Golden, Director of Publishing, Multiview, 469-420-2630 | Download media kit
Brie Ragland, Executive Editor, Multiview, 469-420-2604| Contribute news

The Society of Interventional Oncology
2001 K Street NW, 3rd Floor North | Washington, DC 20006
202-367-1164 | Contact Us | MailScanner has detected a possible fraud attempt from "sm1.multiview.com" claiming to be www.sio-central.org

Click here to unsubscribe.

Learn how to add us to your safe sender list so our emails get to your inbox.

ADVERTISE

PAST ISSUES

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063